Posted by Michael Wonder on 23 Jan 2024
Lower drug costs are just a federal license away. But they require Biden Administration leadership.
23 January 2024 - It’s a longstanding Government failure to never use federal “march-in” licensing rights to lower drug prices. It’s also a mistake to limit them to only a few cases.
In December the White House announced a new draft guidance that allows federal agencies to grant non-voluntary licenses to patents on inventions funded with taxpayer dollars. These are called “march-in” rights, and they allow the Government to force licensing, when necessary, to remedy an abuse or nonuse of such patented inventions.
